Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Yamanouchi develops potent and selective PDE IV inhibitors

Sep. 25, 1997

Synaptic identifies potent, selective alpha1a-adrenoceptor antagonist

Sep. 25, 1997

Nonsteroidal inhibitors of steroid C17,20-lyase developed at Yamanouchi

Sep. 25, 1997

Spotlight on bisphosphonates in osteoporosis

Sep. 25, 1997

LY-303366: efficacy in rabbits with invasive pulmonary aspergillosis

Sep. 25, 1997

AIDS dementia reversed by highly active antiretroviral therapy

Sep. 25, 1997

Short-term efficacy and safety of T-20 in HIV infection

Sep. 25, 1997

Oxandrolone + glutamine for HIV-associated wasting

Sep. 25, 1997

BioChem Therapeutic synthesizes antiangiogenic fumagillin analogues

Sep. 24, 1997

Lilly presents structurally novel thrombin inhibitors

Sep. 24, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....